Works about OSIMERTINIB

Results: 334

Positive Osimertinib Patch Test in a Bullous Lichenoid Drug Reaction.

Published in:

Contact Dermatitis (01051873), 2025, v. 93, n. 2, p. 165, doi. 10.1111/cod.14810

By:

Marcombes, Clarisse;
Bel Hareth, Kamar;
Mazoyer, Héloïse;
Solinas, Sabina;
Ingen‐Housz‐Oro, Saskia;
Assier, Haudrey

Publication type:

Article

Electrocardiographic changes in QTc interval and other parameters associated with osimertinib therapy.

Published in:

Frontiers in Oncology, 2025, p. 1, doi. 10.3389/fonc.2025.1612758

By:

Pan, Yilin;
Peng, Kexin;
Jiang, Yichuan;
Yang, Ping;
Du, Beibei;
He, Yuquan

Publication type:

Article

LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154).

Published in:

Lung Cancer: Targets & Therapy, 2025, v. 16, p. 51, doi. 10.2147/LCTT.S520833

By:

Luo, Faustine;
Arter, Zhaohui;
Ou, Sai-Hong Ignatius;
Nagasaka, Misako

Publication type:

Article

Design, Synthesis, and Evaluation of Novel 2,4‐disubstituted Pyrimidine Derivatives as Double Mutant Epidermal Growth Factor Receptor‐L858R/T790M Tyrosine Kinase Inhibitors.

Published in:

Journal of Biochemical & Molecular Toxicology, 2025, v. 39, n. 1, p. 1, doi. 10.1002/jbt.70077

By:

Ahmad, Iqrar;
Patel, Harun

Publication type:

Article

Improvements in the Synthesis of the Third‐Generation EGFR Inhibitor Osimertinib.

Published in:

Helvetica Chimica Acta, 2021, v. 104, n. 11, p. 1, doi. 10.1002/hlca.202100066

By:

Voulgari, Pinelopi;
Alivertis, Dimitrios;
Skobridis, Konstantinos

Publication type:

Article

Expert opinion on adjuvant treatment with osimertinib in patients with non-small cell lung carcinoma after radical tumor resection.

Published in:

Oncology in Clinical Practice (2450-1654), 2023, v. 19, n. 4, p. 205, doi. 10.5603/OCP.2023.0018

By:

Langfort, Renata;
Krzakowski, Maciej;
Kowalski, Dariusz M.;
Krenke, Rafał;
Orłowski, Tadeusz;
Rzyman, Witold;
Wasąg, Bartosz

Publication type:

Article

Expert opinion on adjuvant treatment with osimertinib in patients with non-small cell lung carcinoma after radical tumor resection.

Published in:

Nowotwory, 2023, v. 73, n. 3, p. 187, doi. 10.5603/njo.96212

By:

Langfort, Renata;
Krzakowski, Maciej;
Kowalski, Dariusz M.;
Krenke, Rafał;
Orłowski, Tadeusz;
Rzyman, Witold;
Wasąg, Bartosz

Publication type:

Article

Real-World Data on Osimertinib-Associated Cardiac Toxicity.

Published in:

Journal of Clinical Medicine, 2025, v. 14, n. 5, p. 1754, doi. 10.3390/jcm14051754

By:

Agbarya, Abed;
Raphael, Ari;
Gantz Sorotsky, Hadas;
Rottenberg, Yakir;
Šebek, Viktor;
Radonjic, Dejan;
Yakobson, Alexander;
Arnon, Johnathan;
Shalata, Walid

Publication type:

Article

A Case of Rapidly Progressive Diabetic Nephropathy Induced by Osimertinib.

Published in:

2023

By:

Karasawa, Kazunori;
Akiyama, Ken-ichi;
Akihisa, Taro;
Miyabe, Yoei;
Nitta, Kosaku;
Hoshino, Junichi

Publication type:

Case Study

Osimertinib-Induced Toxic Epidermal Necrolysis – A Case Report.

Published in:

Contributions / Prilozi (1857-9345), 2024, v. 45, n. 3, p. 77, doi. 10.2478/prilozi-2024-0025

By:

Crvenkova, Simonida;
Popova, Maja;
Crvenkova, Labina;
Lazarevska, Antonija

Publication type:

Article

Osimertinib Efficacy and Safety in Treating Epidermal Growth Factor Receptor Mutation‐Positive Advanced Non–Small‐Cell Lung Cancer: A Meta‐Analysis.

Published in:

Clinical Pharmacology in Drug Development, 2025, v. 14, n. 1, p. 5, doi. 10.1002/cpdd.1483

By:

Zhao, Mengmeng;
Zhang, Jian;
Gao, Jie;
Wang, Jianping;
Ma, Zhenkai

Publication type:

Article

LINC01559 drives osimertinib resistance in NSCLC through a ceRNA network regulating miR-320a/IGF2BP3 axis.

Published in:

Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2025.1592846

By:

Xu, Leidi;
Zhang, Yibo;
Xing, Liangliang;
Zhou, Ying;
Chang, Ning;
Xi, Hangtian;
Xu, Xiangrui;
Zhang, Jian

Publication type:

Article

Adverse event profiles of EGFR-TKI: network meta-analysis and disproportionality analysis of the FAERS database.

Published in:

Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2025.1519849

By:

Shi, Jing;
Liu, Xinya;
Gao, Mengjiao;
Yu, Jian;
Chai, Ting;
Jiang, Yun;
Li, Jiawei;
Zhang, Yuanming;
Wu, Li

Publication type:

Article

Bilateral Hemorrhagic Occlusive Retinal Vasculitis Induced by Osimertinib in a Patient with Non-Small Cell Lung Cancer.

Published in:

2024

By:

Park, No Hae;
Park, Bo Hyun;
Kwon, Han Jo;
Park, Sung Who;
Byon, Iksoo

Publication type:

Case Study

Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non--Small Cell Lung Cancer: Updated Analysis of the RESET Study.

Published in:

Cancer Research & Treatment, 2023, v. 55, n. 4, p. 1152, doi. 10.4143/crt.2023.493

By:

Taeyun Kim;
Tae Won Jang;
Chang Min Choi;
Mi-Hyun Kim;
Sung Yong Lee;
Yoon Soo Chang;
Kye Young Lee;
Seung Joon Kim;
Sei Hoon Yang;
Jeong Seon Ryu;
Jeong Eun Lee;
Shin Yup Lee;
Chan Kwon Park;
Sang Hoon Lee;
Seung Hun Jang;
Seong Hoon Yoon;
Hyung-Joo Oh

Publication type:

Article

Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer.

Published in:

Cancer Research & Treatment, 2023, v. 55, n. 1, p. 112, doi. 10.4143/crt.2022.381

By:

Jang Ho Lee;
Eun Young Kim;
Cheol-Kyu Park;
Shin Yup Lee;
Min Ki Lee;
Seong-Hoon Yoon;
Jeong Eun Lee;
Sang Hoon Lee;
Seung Joon Kim;
Sung Yong Lee;
Jun Hyeok Lim;
Tae-Won Jang;
Seung Hun Jang;
Kye Young Lee;
Seung Hyeun Lee;
Sei Hoon Yang;
Dong Won Park;
Chan Kwon Park;
Hye Seon Kang;
Chang Dong Yeo

Publication type:

Article

Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non–Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI.

Published in:

Cancer Research & Treatment, 2023, v. 55, n. 1, p. 344, doi. 10.4143/crt.2021.1603

By:

Hye Ryeon Kim;
Hyunji Jo;
Hongsik Kim;
Joohyun Hong;
Sehhoon Park;
Hyun Ae Jung;
Se-Hoon Lee;
Jin-Seok Ahn;
Myung-Ju Ahn

Publication type:

Article

A Phase II Trial of Osimertinib as the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1.

Published in:

Cancer Research & Treatment, 2021, v. 53, n. 1, p. 93, doi. 10.4143/crt.2020.459

By:

Cheol-Kyu Park;
Hyun-Ju Cho;
Yoo-Duk Choi;
In-Jae Oh;
Young-Chul Kim

Publication type:

Article

Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.

Published in:

Cancer Research & Treatment, 2020, v. 52, n. 1, p. 284, doi. 10.4143/crt.2019.200

By:

Myung-Ju Ahn;
Ji-Youn Han;
Dong-Wan Kim;
Byoung Chul Cho;
Jin-Hyoung Kang;
Sang-We Kim;
James Chih-Hsin Yang;
Tetsuya Mitsudomi;
Jong Seok Lee

Publication type:

Article

Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment.

Published in:

Cancer Research & Treatment, 2018, v. 50, n. 4, p. 1164, doi. 10.4143/crt.2017.460

By:

Jeng-Sen Tseng;
Tsung-Ying Yang;
Kun-Chieh Chen;
Kuo-Hsuan Hsu;
Yen-Hsiang Huang;
Kang-Yi Su;
Sung-Liang Yu;
Gee-Chen Chang

Publication type:

Article

Successful Chemotherapy for Diffuse Cystic Lung Metastases during Targeted Therapy with Osimertinib in a Patient with Non-Small-Cell Lung Cancer: A Literature Review and a Rare Case Report.

Published in:

Case Reports in Oncology, 2023, v. 16, n. 1, p. 1409, doi. 10.1159/000534711

By:

Matsukida, Akira;
Ogawa, Takunori;
Tanigaki, Tomomi;
Serizawa, Yusuke;
Nishimura, Masashi;
Igarashi, Shunya;
Kato, Yoshiki;
Kawana, Akihiko;
Kimizuka, Yoshifumi

Publication type:

Article

Combination of Osimertinib with Concurrent Chemotherapy and Hormonal Therapy for Synchronous NSCLC, Hormone Receptor-Positive Breast Cancer, and Triple-Negative Breast Cancer: Case Report.

Published in:

Case Reports in Oncology, 2023, v. 16, n. 1, p. 1080, doi. 10.1159/000533783

By:

Park, Changsu L.;
Moria, Feras;
Saleh, Ramy R.

Publication type:

Article

Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report.

Published in:

Case Reports in Oncology, 2023, v. 16, n. 1, p. 1100, doi. 10.1159/000533826

By:

Saito, Zentaro;
Imakita, Takuma;
Ito, Takanori;
Oi, Issei;
Kanai, Osamu;
Fujita, Kohei;
Tachibana, Hiromasa;
Mio, Tadashi

Publication type:

Article

Bone Metastasis of Non-Small-Cell Lung Cancer Showing Pathological Complete Response to Osimertinib Monotherapy.

Published in:

2021

By:

Shintani, Hiroshi;
Oura, Shoji;
Yamaguchi, Tomoyuki;
Makimoto, Shinichiro

Publication type:

Case Study

Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation.

Published in:

Case Reports in Oncology, 2021, v. 14, n. 2, p. 1085, doi. 10.1159/000516404

By:

Nguyen, Thai Hoa Thi;
Pham, Xuan Dung;
Dao, Khanh Linh;
Vo, Thanh Toan

Publication type:

Article

Successful Rechallenge with Osimertinib after Very Acute Onset of Drug-Induced Pneumonitis.

Published in:

Case Reports in Oncology, 2021, v. 14, n. 2, p. 733, doi. 10.1159/000516274

By:

Mohammed, Turab;
Mangeshkar, Shaunak;
Rathmann, Joerg

Publication type:

Article

Osimertinib showed efficacy on contralateral multiple ground-glass nodules after segmentectomy for lung adenocarcinoma harboring primary EGFR-T790M mutation: a case report and review of the literature.

Published in:

2022

By:

Dong, Haijun;
Zhang, Jianbin;
Min, Weiwei;
Shen, Qibin

Publication type:

Case Study

Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.

Published in:

2024

By:

Han, Ruoshuang;
Guo, Haoyue;
Shi, Jinpeng;
Zhao, Sha;
Jia, Yijun;
Liu, Xiaozhen;
Liu, Yiwei;
Cheng, Lei;
Zhao, Chao;
Li, Xuefei;
Zhou, Caicun

Publication type:

Correction Notice

Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.

Published in:

BMC Medicine, 2024, v. 22, n. 1, p. 1, doi. 10.1186/s12916-024-03389-w

By:

Han, Ruoshuang;
Guo, Haoyue;
Shi, Jinpeng;
Zhao, Sha;
Jia, Yijun;
Liu, Xiaozhen;
Liu, Yiwei;
Cheng, Lei;
Zhao, Chao;
Li, Xuefei;
Zhou, Caicun

Publication type:

Article

METTL16-dependent miR-146b-5p m6A modification remodeling sensitize NSCLC to osimertinib via activating PI3K/AKT signaling.

Published in:

BMC Cancer, 2025, v. 25, n. 1, p. 1, doi. 10.1186/s12885-025-14041-y

By:

Sang, Hongyang;
Liu, Jinlong;
Chen, Xifang;
Zeng, Yingou

Publication type:

Article

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer.

Published in:

Molecular Cancer, 2021, v. 20, n. 1, p. 1, doi. 10.1186/s12943-021-01307-9

By:

Wu, Shaocong;
Luo, Min;
To, Kenneth K. W.;
Zhang, Jianye;
Su, Chaoyue;
Zhang, Hong;
An, Sainan;
Wang, Fang;
Chen, Da;
Fu, Liwu

Publication type:

Article

Influence of interleukin-6 on the pharmacokinetics and pharmacodynamics of osimertinib in patients with non-small cell lung cancer.

Published in:

Cancer Chemotherapy & Pharmacology, 2025, v. 95, n. 1, p. 1, doi. 10.1007/s00280-025-04772-x

By:

Yokota, Hayato;
Sato, Kazuhiro;
Sakamoto, Sho;
Okuda, Yuji;
Takeda, Masahide;
Akamine, Yumiko;
Nakayama, Katsutoshi;
Miura, Masatomo

Publication type:

Article

Liquid Biopsy in EGFR -Mutated Advanced NSCLC from T790M to MET Amplification: Clinical Implications and Possibilities in the Resistance Setting.

Published in:

Journal of Molecular Pathology, 2023, v. 4, n. 2, p. 81, doi. 10.3390/jmp4020009

By:

Della Gravara, Luigi;
Battiloro, Ciro;
Avellino, Aniello;
Caputo, Francesca;
D'Aniello, Carmine;
Rocco, Danilo

Publication type:

Article

A rare epidermal growth factor receptor T790M/cis-C797S/L718Q compound mutation in a lung adenocarcinoma patient who did not derive any benefit from combination therapy with afatinib and bevacizumab.

Published in:

SAGE Open Medical Case Reports, 2025, p. 1, doi. 10.1177/2050313X251319381

By:

Meng, Xiaopeng;
Liu, Jingyi;
Wu, Xiaohui;
Peng, Pei

Publication type:

Article

From ICU to long survival.

Published in:

Oncolog-Hematolog, 2024, n. 69, p. 37

By:

Muntenaşu, Ana-Maria;
Cârlan, Ioana-Roxana;
Cojocaru, Eva-Maria

Publication type:

Article

Prolonged survival in EGFR-mutant lung adenocarcinoma: the power of targeted and combination therapies.

Published in:

Oncolog-Hematolog, 2024, n. 69, p. 33

By:

Grigore, Alina-Lavinia

Publication type:

Article

Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro Study.

Published in:

Biomedicines, 2024, v. 13, n. 7, p. 1412, doi. 10.3390/biomedicines12071412

By:

Fukuda, Shota;
Suda, Kenichi;
Hamada, Akira;
Oiki, Hana;
Ohara, Shuta;
Ito, Masaoki;
Soh, Junichi;
Mitsudomi, Tetsuya;
Tsutani, Yasuhiro

Publication type:

Article

A Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and Safety.

Published in:

Biomedicines, 2023, v. 11, n. 9, p. 2501, doi. 10.3390/biomedicines11092501

By:

Fukuhara, Tatsuro;
Imai, Kazuhiro;
Nakagawa, Taku;
Igusa, Ryotaro;
Yokota, Hayato;
Watanabe, Kana;
Suzuki, Aya;
Morita, Mami;
Onodera, Ren;
Inoue, Akira;
Miura, Masatomo;
Minamiya, Yoshihiro;
Maemondo, Makoto

Publication type:

Article

UBL3 Interacts with Alpha-Synuclein in Cells and the Interaction Is Downregulated by the EGFR Pathway Inhibitor Osimertinib.

Published in:

Biomedicines, 2023, v. 11, n. 6, p. 1685, doi. 10.3390/biomedicines11061685

By:

Chen, Bin;
Hasan, Md. Mahmudul;
Zhang, Hengsen;
Zhai, Qing;
Waliullah, A. S. M.;
Ping, Yashuang;
Zhang, Chi;
Oyama, Soho;
Mimi, Mst. Afsana;
Tomochika, Yuna;
Nagashima, Yu;
Nakamura, Tomohiko;
Kahyo, Tomoaki;
Ogawa, Kenji;
Kaneda, Daita;
Yoshida, Minoru;
Setou, Mitsutoshi

Publication type:

Article

PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC).

Published in:

Biomedicines, 2022, v. 10, n. 8, p. N.PAG, doi. 10.3390/biomedicines10081893

By:

Pantazaka, Evangelia;
Ntzifa, Aliki;
Roumeliotou, Argyro;
Lianidou, Evi;
Georgoulias, Vassilis;
Kotsakis, Athanasios;
Kallergi, Galatea

Publication type:

Article

Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non‐small‐cell lung cancer harboring EGFR mutations: Results from a real‐world study in South Korea.

Published in:

Cancer Medicine, 2021, v. 10, n. 17, p. 5809, doi. 10.1002/cam4.4127

By:

Kim, Taeyun;
Jang, Tae Won;
Choi, Chang Min;
Kim, Mi‐Hyun;
Lee, Sung Yong;
Park, Cheol‐Kyu;
Chang, Yoon Soo;
Lee, Kye Young;
Kim, Seung Joon;
Yang, Sei Hoon;
Ryu, Jeong Seon;
Lee, Jeong Eun;
Lee, Shin Yup;
Park, Chan Kwon;
Lee, Sang Hoon;
Jang, Seung Hun;
Yoon, Seong Hoon

Publication type:

Article

Real‐world outcomes of NSCLC patients receiving tissue or circulating tumor DNA‐guided osimertinib treatment.

Published in:

Cancer Medicine, 2019, v. 8, n. 13, p. 5939, doi. 10.1002/cam4.2485

By:

Su, Po‐Lan;
Yang, Szu‐Chun;
Chen, Yi‐Lin;
Wu, Yi‐Lin;
Lin, Chia‐Ying;
Chang, Wei‐Yuan;
Tseng, Yau‐Lin;
Lai, Wu‐Wei;
Ho, Chung‐Liang;
Lin, Chien‐Chung;
Su, Wu‐Chou

Publication type:

Article

Leukocytes telomere length as a biomarker of adverse drug reactions induced by Osimertinib in advanced non-small cell lung cancer.

Published in:

Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-77935-0

By:

Trachu, Narumol;
Reungwetwattana, Thanyanan;
Meanwatthana, Jennis;
Sukasem, Chonlaphat;
Majam, Teerapat;
Saengsiwaritt, Wacharapol;
Jittikoon, Jiraphun;
Udomsinprasert, Wanvisa

Publication type:

Article

MicroRNA-130a-3p regulates osimertinib resistance by targeting runt-related transcription factor 3 in lung adenocarcinoma.

Published in:

Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-76196-1

By:

Shintani, Takuya;
Shun, Yu-Ting;
Toyozumi, Yuji;
Ikemura, Kenji;
Shiroyama, Takayuki;
Nagatomo, Izumi;
Jingushi, Kentaro;
Takeda, Yoshito;
Kumanogoh, Atsushi;
Okuda, Masahiro

Publication type:

Article

Chromosomal Instability Is Associated with cGAS–STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung Cancer.

Published in:

Cells (2073-4409), 2025, v. 14, n. 6, p. 447, doi. 10.3390/cells14060447

By:

Yonesaka, Kimio;
Kurosaki, Takashi;
Tanizaki, Junko;
Kawakami, Hisato;
Tanaka, Kaoru;
Maenishi, Osamu;
Takamura, Shiki;
Sakai, Kazuko;
Chiba, Yasutaka;
Teramura, Takeshi;
Goto, Hiroki;
Otsuka, Eri;
Okida, Hiroaki;
Funabashi, Masanori;
Hashimoto, Yuuri;
Hirotani, Kenji;
Kamai, Yasuki;
Kagari, Takashi;
Nishio, Kazuto;
Kakimi, Kazuhiro

Publication type:

Article

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR -Activating Mutation.

Published in:

Cells (2073-4409), 2022, v. 11, n. 14, p. N.PAG, doi. 10.3390/cells11142201

By:

Nishihara, Shigetoshi;
Yamaoka, Toshimitsu;
Ishikawa, Fumihiro;
Ohmori, Tohru;
Ando, Koichi;
Kusumoto, Sojiro;
Kishino, Yasunari;
Manabe, Ryo;
Hasebe, Yuki;
Sagara, Hironori;
Yoshida, Hitoshi;
Tsurutani, Junji

Publication type:

Article

OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs.

Published in:

Cells (2073-4409), 2021, v. 10, n. 5, p. 1148, doi. 10.3390/cells10051148

By:

Kast, Richard E.;
Halatsch, Marc-Eric;
Rosell, Rafael;
La Monica, Silvia

Publication type:

Article

Emerging a Novel VOPP1-EGFR Fusion Coexistent With T790M as an Acquired Resistance Mechanism to Prior Icotinib and Sensitive to Osimertinib in a Patient With EGFR L858R Lung Adenocarcinoma: A Case Report.

Published in:

Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.720819

By:

Wang, Xia;
Peng, Weiwei;
Zeng, Zhimin;
Cai, Jing;
Liu, Anwen

Publication type:

Article

Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel EGFR Exon 20 Insertion D770_N771insGT and Multiple Brain Metastases.

Published in:

Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.733276

By:

Zhi, Xiaoyu;
Luo, Jiancheng;
Li, Weiwei;
Wang, Jinliang;
Wang, Yuying;
Cai, Yi;
Yan, Xiang

Publication type:

Article

Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib.

Published in:

Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.727312

By:

Wang, Yu;
Liu, Songtao;
Feng, Alei;
Luo, Huan;
Hu, Jinwei;
Wang, Kai;
Dong, Wei

Publication type:

Article